Glenmark moves closer to HIV drug launch

Main symptoms of acute HIV infection. Sources ...

Image via Wikipedia

Glenmark Pharmaceuticals has completed the third phase of human trials of Crofelemer, a new drug to treat HIV-related diarrhoea that could rake in over $80 million. The company has the right to launch the product in 140 countries, excluding the US, Europe, Japan and China, where its partners have marketing rights, Glenmark said in a statement.

In the US and the Europe, Salix Pharmaceuticals has the rights to sell the drug while in Japan and China, Luye Pharmaceuticals has the rights to sell the product, which is the first of its type. Glenmark is the sole global supplier of its active pharmaceutical ingredient (API) to Salix Pharmaceuticals, except in China. Indian drugmakers have mastered developing low cost version of off-patent drugs and Crofelemer would be the country’s first new drug, if it is successfully launched.

Enhanced by Zemanta


Post a Comment

All comments are moderated. Please post no spam

Disclaimer & Privacy Policies

(c) Mrs. Ruby Christy. This site and contents are owned by Mrs. Ruby Christy;
Use of this website and/or services offered by us indicates your acceptance of our Disclaimer& Privacy Policies.

Information and opinions provided on this website ( has been independently obtained from sources believed to be reliable. However, such information may include inaccuracies, errors or omissions. and its affiliates, information providers or content providers and R.John Christy and his Family shall have no liability to you or third parties for the accuracy, completeness, timeliness or correct sequencing of information available on this website or feeds, or for any decision made or action taken by you in reliance upon such information, or for the delay or interruption of such information.,its affiliates, information providers ,content providers and R. John Christy and his Family shall have no liability for investment decisions or other actions taken or made by you based on the information provided on this website. Any action you choose to take in the markets is totally your own responsibility. and R. John Christy and his Family will not be liable for any, direct or indirect, consequential or incidental damages or loss arising out of the use of this information. This information is neither an offer to sell nor solicitation to buy any of the securities mentioned herein. Opinions expressed by R. John Christy are his own and not of his past, present and future employers.
The DoubleClick DART cookie is used by Google in the ads served on this websites displaying AdSense for content ads. When users visit this website and either view or click on an ad, a cookie may be dropped on that end user's browser.
  • Google, as a third party vendor, uses cookies to serve ads on this site.
  • Google's use of the DART cookie enables it to serve ads to your users based on their visit to this site and other sites on the Internet.
  • Users may opt out of the use of the DART cookie by visiting the Google ad and content network privacy policy.
  • never collects any personal information of visitors.